New Hampshire will receive a little over $70,000 as part of a multi-state settlement with a pharmaceutical company accused of off-label marketing and kickbacks for two of its cancer drugs, the attorney general’s office announced Friday.
Celgene Corporation is paying a total of $280 million to the federal government and 28 states across the country that sued the company over its marketing and payment practices.
The company faced allegations that it downplayed negative outcomes associated with Thalomid and Revlimid, and that it paid prescribers of those drugs to participate in speaking programs or take on other prominent consulting roles.
The company denies any wrongdoing, and says that it settled the case to avoid “the uncertainty, distraction and expense of protracted litigation.”
